Welcome to the web pages of the Radford Group

Our research

One of the most fascinating questions in biology is how proteins are able to fold and assemble into complex, functional entities given just the information provided by the amino acid sequence. A related, equally important facet of the same fundamental question is how protein misfolding can lead to protein aggregation, cellular dysfunction and disease. These issues are the major focus of my research and are tackled using a broad range of techniques including protein chemistry, structural molecular biology, chemical biology, cell biology and biophysical methods.

Current major projects:

  • Mechanism(s) of protein misfolding and assembly into amyloid
  • Outer Membrane Protein (OMP) folding – The role of chaperones & BAM
  • Stabilising proteins of therapeutic interest against aggregation
  • Method development (MS, NMR, single molecule, biophysical methods)
    • Misfolding picture

      How and why proteins aggregate into amyloid are important fundamental questions that have far-reaching biomedical importance. Focusing on the proteins (β2-microglobulin (dialysis related amyloidosis)); amylin (type II diabetes); α-synuclein (Parkinson’s) and Aβ (Alzheimer’s), work in the group aims to map the structural mechanism of amyloid formation and to develop reagents to control aggregation in vitro and in vivo. Recent highlights include structure determination of oligomers (NMR (Karamanos (2019) eLife)) and fibrils (cryoEM (with Ranson) (Iadanza (2018) Nature Comms.)); discovery of small molecules that modulate amyloid formation (ESI-MS (Young (2015) Nature Chem.)); demonstration that early protein-protein interactions in amyloid formation are specific and can be targeted to arrest assembly in vitro and in vivo (Doherty (2020) Nature Struct. Mol. Biol.).

      OMP picture

      How OMPs fold and assemble into the asymmetric outer-membrane (OM) of Gram-negative bacteria is a second research theme in our lab. In a collaborative multidisciplinary team (with David Brockwell, Neil Ranson, Roman Tuma and Ian Collinson (Bristol)) we are investigating how OMPs cross the inner-membrane via SecYEG (Fessl (2018) eLife)); traverse the periplasm aided by chaperones (Skp/SurA) (Schiffrin (2016) Nature SMB, Calabrese (2020) Nature Comms)), fold into membranes in vitro (Husymans, (2010) PNAS) and in vivo catalysed by the essential β-barrel membrane machinery (BAM) (Iadanza (2016) Nature Comms, Schiffrin (2017) JMB). Building on these insights we are currently exploring the dynamic motions of BAM during catalysis and how this can be harnessed to generate new antibacterial agents against Gram-negative pathogens.

      Therapeutic engineering

      We are also exploiting our knowledge of protein folding/aggregation to practical benefit by screening amyloidogenic proteins, as well as proteins of interest to biopharma, for hotspots that cause aggregation. By coupling aggregation to bacterial growth using a tripartite β-lactamase fusion construct we have discovered small molecules that prevent aggregation of amyloidogenic proteins (Saunders (2016) Nature Chem. Biol.). With David Brockwell and our collaborators in AstraZeneca, we recently combined the assay with directed evolution to enhance the resilience of biopharmaceutically-relevant antibodies to aggregation (Ebo (2020) Nature Comms.). Finally, in collaboration with David Brockwell and Nik Kapur (Mechanical Engineering, Leeds), we are examining how flow fields enhance, or cause, aggregation by flow-induced protein deformations (Dobson (2017) PNAS, Willis (2020) Eng. Rep.).

      Methods picture

      Major developments in methods and instrumentation have played a key role in increasing in our understanding of protein folding and aggregation. Future developments in these fields will also require innovative approaches that cross the boundaries between disciplines. We have been involved in many exciting collaborations to fulfil this aim. With Alison Ashcroft (now emeritus), Frank Sobott and Andrew Wilson we have developed and expanded our arsenal of methods to interrogate protein folding, protein-protein interactions and protein complexes, including MS methods (HDX-MS and fast photochemical oxidation of proteins (FPOP-MS)) to map transient interactions (Cornwell (2018) J. Am. Soc. MS, Cornwell (2019) Analyt. Chem.); ion mobility MS to map oligomers formed during aggregation (Young (2017) Chem. Sci.) and ligand binding to amyloidogenic monomers and oligomers (Young (2016) Nature Chem.) and ultrarapid crosslinking to map protein-chaperone interactions (Horne (2018) Angewandte Chemie, Calabrese (2020) Nature Comms). Developments in NMR methods remain a mainstay of our laboratory activities, whilst, in collaboration with David Brockwell we are involved in exciting developments in the use of the AFM and flow devices for measurements of protein unfolding and protein binding.

“ I think that we shall be able to get a more thorough understanding of the nature of disease in general by investigating the molecules that make up the human body, including the abnormal molecules, and that this understanding will permit...the problem of disease to be attacked in a more straightforward manner such that new methods of therapy will be developed. ”